Go Pro
TSE:CTX

Crescita Therapeutics Q1 2026 Earnings Report

Crescita Therapeutics logo
C$0.79 0.00 (0.00%)
As of 06/4/2026

Crescita Therapeutics EPS Results

Actual EPS
-C$0.06
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Crescita Therapeutics Revenue Results

Actual Revenue
$5.64 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Crescita Therapeutics Announcement Details

Quarter
Q1 2026
Time
Before Market Opens
Conference Call Date
Monday, May 11, 2026
Conference Call Time
7:30AM ET

Earnings Documents

Crescita Therapeutics Earnings Headlines

A letter from Shannon Stansberry
Porter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief. It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live.tc pixel
See More Crescita Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Crescita Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Crescita Therapeutics and other key companies, straight to your email.

About Crescita Therapeutics

Crescita Therapeutics (TSE:CTX) Inc is a Canadian commercial dermatology company with in-house research & development and manufacturing capabilities. The company offers a portfolio of non-prescription skincare products and early to commercial-stage prescription drug products and owns multiple proprietary drug delivery platforms that support the development of patented formulations that can facilitate the delivery of active ingredients into or through the skin. The firm generates its revenue in the form of product sales and out-licensing revenue.

View Crescita Therapeutics Profile